{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:47:19Z","timestamp":1767962839158,"version":"3.49.0"},"reference-count":135,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2014,2,3]],"date-time":"2014-02-03T00:00:00Z","timestamp":1391385600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0087791","type":"journal-article","created":{"date-parts":[[2014,2,3]],"date-time":"2014-02-03T22:05:02Z","timestamp":1391465102000},"page":"e87791","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prediction of Cancer Drugs by Chemical-Chemical Interactions"],"prefix":"10.1371","volume":"9","author":[{"given":"Jing","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Yan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Yue","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Dong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,2,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"A Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.1021\/jm200504p","article-title":"What do medicinal chemists actually make? A 50-year retrospective","volume":"54","author":"WP Walters","year":"2011","journal-title":"J Med Chem"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"e17668","DOI":"10.1371\/journal.pone.0017668","article-title":"Predicting protein phenotypes based on protein-protein interaction network","volume":"6","author":"L Hu","year":"2011","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"e14556","DOI":"10.1371\/journal.pone.0014556","article-title":"Predicting functions of proteins in mouse based on weighted protein-protein interaction network and protein hybrid properties","volume":"6","author":"L Hu","year":"2011","journal-title":"PLoS One"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"910","DOI":"10.2174\/092986612802084528","article-title":"Prediction of human genes\u2019 regulatory functions based on proteinprotein interaction network","volume":"19","author":"P Gao","year":"2012","journal-title":"Protein Pept Lett"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"e29491","DOI":"10.1371\/journal.pone.0029491","article-title":"Predicting biological functions of compounds based on chemical-chemical interactions","volume":"6","author":"LL Hu","year":"2011","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"e35254","DOI":"10.1371\/journal.pone.0035254","article-title":"Predicting Anatomical Therapeutic Chemical (ATC) Classification of Drugs by Integrating Chemical-Chemical Interactions and Similarities","volume":"7","author":"L Chen","year":"2012","journal-title":"PLoS ONE"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e56517","DOI":"10.1371\/journal.pone.0056517","article-title":"Predicting Chemical Toxicity Effects Based on Chemical-Chemical Interactions","volume":"8","author":"L Chen","year":"2013","journal-title":"PLoS ONE"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"D684","DOI":"10.1093\/nar\/gkm795","article-title":"STITCH: interaction networks of chemicals and proteins","volume":"36","author":"M Kuhn","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"D552","DOI":"10.1093\/nar\/gkp937","article-title":"STITCH 2: an interaction network database for small molecules and proteins","volume":"38","author":"M Kuhn","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/nar\/28.1.27","article-title":"KEGG: Kyoto encyclopedia of genes and genomes","volume":"28","author":"M Kanehisa","year":"2000","journal-title":"Nucleic Acids Research"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"DS Wishart","year":"2006","journal-title":"Nucleic acids research"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"TT Ashburn","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1126\/science.1169920","article-title":"Drug discovery. Repurposing with a difference","volume":"324","author":"MS Boguski","year":"2009","journal-title":"Science"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"14621","DOI":"10.1073\/pnas.1000138107","article-title":"Discovery of drug mode of action and drug repositioning from transcriptional responses","volume":"107","author":"F Iorio","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"96ra76","DOI":"10.1126\/scitranslmed.3002648","article-title":"Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease","volume":"3","author":"JT Dudley","year":"2011","journal-title":"Sci Transl Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"96ra77","DOI":"10.1126\/scitranslmed.3001318","article-title":"Discovery and preclinical validation of drug indications using compendia of public gene expression data","volume":"3","author":"M Sirota","year":"2011","journal-title":"Sci Transl Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e1002503","DOI":"10.1371\/journal.pcbi.1002503","article-title":"Prediction of drug-target interactions and drug repositioning via network-based inference","volume":"8","author":"F Cheng","year":"2012","journal-title":"PLoS Comput Biol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1586\/epr.11.20","article-title":"Recent progress in predicting protein sub-subcellular locations","volume":"8","author":"P Du","year":"2011","journal-title":"Expert Review of Proteomics"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e45944","DOI":"10.1371\/journal.pone.0045944","article-title":"Predicting Metabolic Pathways of Small Molecules and Enzymes Based on Interaction Information of Chemicals and Proteins","volume":"7","author":"YF Gao","year":"2012","journal-title":"PLoS ONE"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/msb4100129","article-title":"Network-based prediction of protein function","volume":"3","author":"R Sharan","year":"2007","journal-title":"Molecular systems biology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.compbiomed.2010.01.001","article-title":"Prediction of protein functions based on function-function correlation relations","volume":"40","author":"KL Ng","year":"2010","journal-title":"Computers in Biology and Medicine"},{"key":"ref23","unstructured":"AMPAC, Semichem, Inc.: Shawnee, KS 66216."},{"key":"ref24","unstructured":"COmprehensive DEscriptors for Structural and Statistical Analysis (CODESSA), Semichem, Inc.: Shawnee, KS 66216."},{"key":"ref25","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/1574893611308020008","article-title":"Prediction of Metabolic Pathway Using Graph Property, Chemical Functional Group and Chemical Structural Set","volume":"8","author":"L Chen","year":"2013","journal-title":"Current Bioinformatics"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jtbi.2008.11.003","article-title":"Use of fuzzy clustering technique and matrices to classify amino acids and its impact to Chou\u2019s pseudo amino acid composition","volume":"257","author":"D Georgiou","year":"2009","journal-title":"Journal of theoretical biology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"e55401","DOI":"10.1371\/journal.pone.0055401","article-title":"Prediction of P53 Mutants (Multiple Sites) Transcriptional Activity Based on Structural (2D&3D) Properties","volume":"8","author":"RG Ramani","year":"2013","journal-title":"PLoS ONE"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/bioinformatics\/bts700","article-title":"ECOH: An Enzyme Commission number predictor using mutual information and a support vector machine","volume":"29","author":"Y Matsuta","year":"2013","journal-title":"Bioinformatics"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e25297","DOI":"10.1371\/journal.pone.0025297","article-title":"Classification and Analysis of Regulatory Pathways Using Graph Property, Biochemical and Physicochemical Property, and Functional Property","volume":"6","author":"T Huang","year":"2011","journal-title":"PLoS ONE"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1089\/106652703322756168","article-title":"Prediction of Protein Function Using Protein-protein Interaction Data","volume":"10","author":"M Deng","year":"2003","journal-title":"Journal of Computational Biology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1093\/bioinformatics\/btl145","article-title":"Exploiting indirect neighbours and topological weight to predict protein function from protein-protein interactions","volume":"22","author":"HN Chua","year":"2006","journal-title":"Bioinformatics"},{"key":"ref32"},{"key":"ref33"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"8113","DOI":"10.1039\/c0dt00292e","article-title":"The status of platinum anticancer drugs in the clinic and in clinical trials","volume":"39","author":"NJ Wheate","year":"2010","journal-title":"Dalton Trans"},{"key":"ref35","first-page":"155","article-title":"Antitumor effect of cisplatin against murine ascites Dalton\u2019s lymphoma","volume":"32","author":"SB Prasad","year":"1994","journal-title":"Indian J Exp Biol"},{"key":"ref36"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/j.1349-7006.2008.00768.x","article-title":"Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)\/T-cell lymphoma and leukemia","volume":"99","author":"M Yamaguchi","year":"2008","journal-title":"Cancer Sci"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study","volume":"29","author":"M Yamaguchi","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref39"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1939-1676.1999.tb01452.x","article-title":"Lomustine (CCNU) for the treatment of resistant lymphoma in dogs","volume":"13","author":"AS Moore","year":"1999","journal-title":"J Vet Intern Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1939-1676.2007.tb02938.x","article-title":"Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma","volume":"21","author":"CF Saba","year":"2007","journal-title":"J Vet Intern Med"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1939-1676.2007.0005.x","article-title":"Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs","volume":"22","author":"AB Flory","year":"2008","journal-title":"J Vet Intern Med"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1939-1676.2006.tb02833.x","article-title":"CCNU in the treatment of canine epitheliotropic lymphoma","volume":"20","author":"LE Williams","year":"2006","journal-title":"J Vet Intern Med"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1751-0813.2011.00690.x","article-title":"CCNU (lomustine) toxicity in dogs: a retrospective study (2002\u201307)","volume":"89","author":"KL Heading","year":"2011","journal-title":"Aust Vet J"},{"key":"ref45","first-page":"386","article-title":"Mitotane for adrenocortical carcinoma treatment","volume":"6","author":"S Hahner","year":"2005","journal-title":"Curr Opin Investig Drugs"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJM199004263221705","article-title":"Clinical Features of Adrenocortical Carcinoma, Prognostic Factors, and the Effect of Mitotane Therapy","volume":"322","author":"J-P Luton","year":"1990","journal-title":"New England Journal of Medicine"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1001\/jama.1981.03320150054033","article-title":"Metastatic adrenal cortical carcinoma. Prolonged regression with mitotane therapy","volume":"246","author":"J Jarabak","year":"1981","journal-title":"JAMA"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"M Terzolo","year":"2007","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1210\/jc.2012-2851","article-title":"Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5alpha-reductase, explaining the need for personalized glucocorticoid and androgen replacement","volume":"98","author":"V Chortis","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref50","first-page":"2442","article-title":"Methylazoxyprocarbazine, the active metabolite responsible for the anticancer activity of procarbazine against L1210 leukemia","volume":"49","author":"DS Swaffar","year":"1989","journal-title":"Cancer Res"},{"key":"ref51"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2009-11-253211","article-title":"Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)","volume":"116","author":"TV Halbsguth","year":"2010","journal-title":"Blood"},{"key":"ref53"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.bjc.6603660","article-title":"Temozolomide as salvage treatment in primary brain lymphomas","volume":"96","author":"M Reni","year":"2007","journal-title":"Br J Cancer"},{"key":"ref55"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/10428190601186150","article-title":"Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma","volume":"48","author":"I Majolino","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1038\/sj.leu.2403097","article-title":"A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia","volume":"17","author":"EA Kolb","year":"2003","journal-title":"Leukemia"},{"key":"ref58"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1200\/JCO.1989.7.11.1646","article-title":"A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial","volume":"7","author":"DC Hohn","year":"1989","journal-title":"J Clin Oncol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3109\/10428194.2010.491137","article-title":"Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed\/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium","volume":"51","author":"AK Gopal","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1200\/JCO.1999.17.12.3776","article-title":"Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin\u2019s lymphoma","volume":"17","author":"CH Moskowitz","year":"1999","journal-title":"J Clin Oncol"},{"key":"ref62"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1008312432416","article-title":"Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study","volume":"10","author":"MJ Rummel","year":"1999","journal-title":"Ann Oncol"},{"key":"ref64"},{"key":"ref65"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2011.05.005","article-title":"Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results","volume":"38","author":"M Aapro","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1023\/A:1008364222793","article-title":"Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older","volume":"10","author":"C Vogel","year":"1999","journal-title":"Ann Oncol"},{"key":"ref68"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.2004.10.047","article-title":"Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both","volume":"22","author":"EA Perez","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12282-011-0316-z","article-title":"Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B","volume":"20","author":"H Hayashi","year":"2013","journal-title":"Breast Cancer"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00280-005-1006-3","article-title":"Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study","volume":"56","author":"GP Stathopoulos","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000055264","article-title":"Xeloda in the treatment of metastatic breast cancer","volume":"57","author":"JL Blum","year":"1999","journal-title":"Oncology"},{"key":"ref73"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1634\/theoncologist.11-4-325","article-title":"Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer","volume":"11","author":"WB Ershler","year":"2006","journal-title":"Oncologist"},{"key":"ref75"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/jcp.2004.025163","article-title":"Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors","volume":"58","author":"S Leibl","year":"2005","journal-title":"J Clin Pathol"},{"key":"ref77"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.2009.22.0541","article-title":"Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer","volume":"27","author":"GR Blumenschein Jr","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref79"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/cncr.11548","article-title":"The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel","volume":"98","author":"TA Hensing","year":"2003","journal-title":"Cancer"},{"key":"ref81"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00000421-199106000-00012","article-title":"Prospective trial of cisplatin, adriamycin, and dacarbazine in metastatic mixed mesodermal sarcomas of the uterus and ovary","volume":"14","author":"TR Baker","year":"1991","journal-title":"Am J Clin Oncol"},{"key":"ref83"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.2007.14.5375","article-title":"Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"26","author":"HJ Burstein","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/annonc\/mdp565","article-title":"An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer","volume":"21","author":"M Kozloff","year":"2010","journal-title":"Ann Oncol"},{"key":"ref86"},{"key":"ref87","first-page":"653","article-title":"The antiandrogen flutamide inhibits growth of mcf-7 human breast-cancer cell-line","volume":"2","author":"M Dimonaco","year":"1993","journal-title":"Int J Oncol"},{"key":"ref88"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF00666056","article-title":"Phase II study of weekly mitoxantrone, 5-fluorouracil, and leucovorin in metastatic breast cancer","volume":"30","author":"L Repetto","year":"1994","journal-title":"Breast Cancer Res Treat"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Rivera E, Chang JC, Semiglazov V, Gorbunova V, Manikhas A, et al. (2012) Eniluracil +5-fluorouracil+leucovorin (EFL) vs. capecitabine phase 2 trial for metastatic breast cancer. Thirty-Fifth Annual CTRC-AACR San Antonio Breast Cancer Symposium. San Antonio, TX. pp. Supplement 3.","DOI":"10.1158\/0008-5472.SABCS12-OT3-3-01"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/jnci\/djn498","article-title":"Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer","volume":"101","author":"A Hackshaw","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"ref92"},{"key":"ref93","first-page":"2382","article-title":"[Successful treatment of advanced esophageal cancer with lymph node metastases by docetaxel, cisplatin and 5-FU followed by salvage lymphadenectomy\u2013a case report]","volume":"37","author":"A Takeno","year":"2010","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref94"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jama.1966.03110120149043","article-title":"Childhood malignant tumors. Concurrent chemotherapy with dactinomycin and vincristine sulfate","volume":"197","author":"DH James Jr","year":"1966","journal-title":"JAMA"},{"key":"ref96"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10792-007-9102-5","article-title":"Localized conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma is amenable to local chemotherapy","volume":"28","author":"CS Yu","year":"2008","journal-title":"Int Ophthalmol"},{"key":"ref98","first-page":"1393","article-title":"The synergistic anti-neoplastic activity of combinations of mitomycins with either 6-thioguanine or 5-fluorouracil","volume":"25","author":"AC Sartorelli","year":"1965","journal-title":"Cancer Res"},{"key":"ref99","first-page":"559","article-title":"Comparative antitumor activities of 7-N-(p-hydroxyphenyl)mitomycin C (M-83) and mitomycin C. J Antibiot (Tokyo)","volume":"36","author":"R Imai","year":"1983"},{"key":"ref100"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1006\/gyno.1999.5461","article-title":"Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: a southwest oncology group study","volume":"74","author":"EA Poplin","year":"1999","journal-title":"Gynecol Oncol"},{"key":"ref102","first-page":"1925","article-title":"[Etoposide (VP-16) in gynecologic malignancy]","volume":"23","author":"K Kanazawa","year":"1996","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0090-8258(91)90061-9","article-title":"Etoposide (VP-16), ifosfamide\/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix","volume":"43","author":"DC Kredentser","year":"1991","journal-title":"Gynecol Oncol"},{"key":"ref104"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1023\/A:1006185805079","article-title":"Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis","volume":"54","author":"PP Peethambaram","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"ref106"},{"key":"ref107","first-page":"419","article-title":"A clinical trial of intravenous bleomycin in the treatment of brain tumors","volume":"12","author":"K Takeuchi","year":"1975","journal-title":"Int J Clin Pharmacol Biopharm"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/0008-5472.CAN-11-0451","article-title":"Preclinical validation of electrochemotherapy as an effective treatment for brain tumors","volume":"71","author":"B Agerholm-Larsen","year":"2011","journal-title":"Cancer Res"},{"key":"ref109"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/sj.onc.1209180","article-title":"Prevention of lung cancer progression by bexarotene in mouse models","volume":"25","author":"Y Wang","year":"2006","journal-title":"Oncogene"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lungcan.2005.05.008","article-title":"The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells","volume":"50","author":"TW Hermann","year":"2005","journal-title":"Lung Cancer"},{"key":"ref112"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.biopha.2004.12.003","article-title":"Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients","volume":"59","author":"F Galetta","year":"2005","journal-title":"Biomed Pharmacother"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa035153","article-title":"The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia","volume":"351","author":"SE Lipshultz","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.ejca.2011.03.022","article-title":"The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium","volume":"47","author":"LM Vrooman","year":"2011","journal-title":"Eur J Cancer"},{"key":"ref116"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0304-3835(81)90059-8","article-title":"DNA damage by anthracycline drugs in human leukemia cells","volume":"13","author":"HS Schwartz","year":"1981","journal-title":"Cancer Lett"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1093\/carcin\/bgq122","article-title":"Topical application of valrubicin has a beneficial effect on developing skin tumors","volume":"31","author":"SM Andersen","year":"2010","journal-title":"Carcinogenesis"},{"key":"ref119"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/bcr3223","article-title":"Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment","volume":"14","author":"RA Steinman","year":"2012","journal-title":"Breast Cancer Res"},{"key":"ref121"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/annonc\/mdg406","article-title":"Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer","volume":"14","author":"E Bajetta","year":"2003","journal-title":"Ann Oncol"},{"key":"ref123"},{"key":"ref124","first-page":"171","article-title":"Influence of fluoxymesterone on in vitro erythropoiesis affected by leukemic cells","volume":"12","author":"GZ Bai","year":"1984","journal-title":"Exp Hematol"},{"key":"ref125"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1207\/S15327914NC330202","article-title":"p53-independent apoptosis induced by genistein in lung cancer cells","volume":"33","author":"F Lian","year":"1999","journal-title":"Nutr Cancer"},{"key":"ref127"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1158\/1535-7163.MCT-10-0572","article-title":"The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss","volume":"9","author":"J Pratap","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"ref129"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00280-012-1943-6","article-title":"A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy","volume":"70","author":"YH Kim","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10637-006-7304-8","article-title":"A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane","volume":"24","author":"JA Ajani","year":"2006","journal-title":"Invest New Drugs"},{"key":"ref132"},{"key":"ref133","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.lungcan.2011.12.002","article-title":"Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and\/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum","volume":"76","author":"B Massuti","year":"2012","journal-title":"Lung Cancer"},{"key":"ref134"},{"key":"ref135","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ejca.2011.01.001","article-title":"A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I\/II study","volume":"47","author":"C Villanueva","year":"2011","journal-title":"Eur J Cancer"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0087791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T08:30:03Z","timestamp":1565166603000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0087791"}},"subtitle":[],"editor":[{"given":"Lukasz","family":"Kurgan","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,2,3]]},"references-count":135,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,2,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0087791","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,3]]}}}